COLLABORATE El Meu Clínic . This link opens in a new tab.
Make a donation
Navigation thread
Navigation thread
Translational genomics and targeted therapies in solid tumours
Make a donation

Featured projects

  • A European Cancer Image Platform Linked to Biological and Health

    Principal investigator: Aleix Prat Aparicio.
    Funder: Horizon 2020 Framework Programme .
    Code: 952103 — EuCanImage.
    Duration: 01/10/2020 - 30/09/2024

  • Identification of mechanisms of response to CDK4/6 inhibition in hormone receptor-positive breast cancer

    Principal investigator: Aleix Prat Aparicio.
    Funder: IRB (Participante); Fundació La Marató de TV3 ; IDIBELL (Participante); IDIBAPS (Sede).
    Code: 201935-30-31-32.
    Duration: 30/07/2020 - 29/07/2023
    Summary:

    Hormone receptor–pos

  • RESCUER. Resistance Under Combinatorial Treatment in ER+ and ER- Breast Cancer.

    Principal investigator: Aleix Prat Aparicio.
    Funder: Horizon 2020 Research and Innovation Framework Programme .
    Code: H2020-SC1-BHC-02-2019 / 847912-2.
    Duration: 01/01/2020 - 31/12/2024

  • Targeting immune checkpoints and metabolic reprogramming synergic vulnerabilities in metastatic colorectal cancer (IMMETCOL)

    Principal investigator: Joan Maurel.
    Funder: Instituto de Salud Carlos III (Sede).
    Duration: 01/01/2020 - 01/01/2022

  • Adoptive cell therapy using CD3+/PD1+ tumor infiltrating lymphocytes in patients with advanced breast cancer

    Principal investigator: Aleix Prat Aparicio.
    Funder: AECC, Fundación Científica Asociación Española Contra el Cáncer ; Hospital Clinic de Baarcelona (Participante); Clínica Universidad de Navarra (Participante); Vall d'Hebron Institut d'Oncologia (Participante); HOSPITAL UNIVERSITARIO 12 DE OCTUBRE (Partic.
    Code: GCAEC19010PRAT.
    Duration: 01/12/2019 - 30/11/2024

  • Treatment of advanced breast cancer with adoptive therapy of CD3+/PD1+ tumor infiltrating lymphocytes

    Principal investigator: Aleix Prat Aparicio.
    Funder: Fundacion AECC .
    Duration: 15/09/2019 - 14/09/2022

  • AACR 2019 - Tailoring systemic treatment of Luminal B breast cancer

    Principal investigator: Patricia Galvan, Aleix Prat Aparicio.
    Funder: Institut d`Investigacions Biomèdiques August Pi i Sunyer (Sede); Breast Cancer Research Foundation-AACR Career Development Awards for Translational Breast Cancer Research .
    Code: BCRF_AACR_18_001.
    Duration: 01/07/2019 - 30/06/2021

  • Caracterización de los linfocitos T CD8+/PD1+ en cáncer de mama avanzado receptor hormonal-positivo con un fenotipo agresivo HER2-enriched.

    Principal investigator: Aleix Prat Aparicio.
    Funder: Merck Farma y Química, S.L .
    Code: 19-IO-011.
    Duration: 01/07/2019 - 30/06/2021

  • Prospective exploratory study for determination of circulating tumor DNA (ctDNA) in blood samples from patients treated for breast cancer in follow-up and without evidence of relapse (B-CRONOS) KEYWORDS : Breast cancer, ctDNA, luminal, high risk

    Principal investigator: Aleix Prat Aparicio.
    Funder: Institut d`Investigacions Biomèdiques August Pi i Sunyer (Sede); Fundación Quiron Salaud ; Fundación Quirón Salud .
    Code: TERAPIA_AMIGOS_18_01.
    Duration: 11/02/2019 - 10/02/2022

  • Targeting the HER2-enriched phenotype in hormone receptor-positive breast cancer. Breast Cancer Now (Breast Cancer Now)

    Duration: 01/01/2019 - 01/01/2022

Major founders

The research of this group can be carried out thanks to the funders.

Contributors

Donations that make possible the research of this group.

More about research
Check job offers

IDIBAPS-FCRB looks for talented professionals to meet the needs that appear periodically.

Enter